Longer life spans, traumatic injuries stimulate global expansion
WELLESLEY, Mass., June 18, 2018 (GLOBE NEWSWIRE) — Longer life spans, the increasing prevalence of neurological disorders (particularly neurodegenerative diseases), stroke and traumatic central nervous system injuries are major drivers of the Global market for neuroprotective agents. A new BCC Research study projects that this market will reach $75.8 billion by 2022 and examines it by indication, agent mechanism of action and geographic region.
Neuroprotection is an approach to treating neurological disorders through the use of therapies developed to protect nerve cells from damage, degeneration and death. Neuroprotective agents in clinical pipelines include small-molecule drugs, therapeutic monoclonal antibodies, gene and cell therapies, and other agents. From a total value of $54.4 billion in 2017, this market is projected to expand at a five-year compound annual growth rate (CAGR) of 6.8%, according to BCC Research’s new report, Neuroprotective Agents: Therapeutic Applications and Global Markets.
Treating neurological disorders has been greatly challenging, in part due to insufficient clinical research. Also, therapeutic limitations exist because the natural protective seal around the brain, called the blood-brain barrier, makes it extremely difficult to effectively diffuse a drug compound into the brain.
Research Highlights
- By 2022, global annual sales for therapeutic monoclonal antibodies are poised to climb by $5 billion, assisted by the highly anticipated introduction of two anti-amyloid antibodies for the treatment of Alzheimer’s disease.
- Gene and cell therapies are expected to generate more than $6.4 billion in combined sales by 2022.
- The market for neuroprotective therapies for traumatic central nervous system injuries, which was virtually nonexistent in 2017, may approach $600 million by 2022.
“Diseases commonly associated with advanced age (such as glaucoma, dementia associated with Alzheimer’s disease, age-related macular degeneration, diabetic retinopathy, and Parkinson’s disease) affect nearly 25% of people older than 60 years,” said Ufuk Ezer, BCC Research analyst and author of this report. “Neuroprotective agents encompass various modes of treatment and collectively offer great commercial value for addressing the treatment needs of a large and sometimes underserved global market.”
RoW Regions Poised To Close Gap
North America accounts for almost 67% of total global sales of neuroprotective agents. Through 2022, strong sales growth is forecast in North America and Asia-Pacific. The rest of the world (RoW; excluding European countries) is projected to have the strongest growth through 2022, mainly due to lagging market penetration of existing products, low pricing pressure in some countries, improvements in access to healthcare, and growing patient populations.
About BCC Research
BCC Research is a publisher of market research reports that provide organizations with intelligence to drive smart business decisions. By partnering with industry experts worldwide, BCC Research provides unbiased measurements and assessments of global markets covering major industrial and technology sectors, including emerging markets. For more information about BCC Research, please visit bccresearch.com. Follow BCC Research on Twitter at @BCCResearch.
CONTACT: Editors/reporters requesting analyst interviews should contact Eric Surber at [email protected].